Ji Hyeon Ju

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis

Hoibin Jeong, Sehui Kim, Beom-Ju Hong et al. · Cancer Research · 2019 · 254 citations

Hyaluronate–Gold Nanoparticle/Tocilizumab Complex for the Treatment of Rheumatoid Arthritis

Hwiwon Lee, Min Young Lee, Suk Ho Bhang et al. · ACS Nano · 2014 · 214 citations

Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation

Kyoung‐Woon Kim, Mi‐La Cho, Sang‐Heon Lee et al. · Immunology Letters · 2007 · 147 citations

Inflammation, Rheumatology, Rheumatoid Disorder +9

Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus

Ji Yeon Lee, Nadimuthu Vinayagamoorthy, Kyungdo Han et al. · Arthritis & Rheumatology · 2015 · 141 citations